Anistreplase

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Anistreplase
Clinical data
Trade namesEminase
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
Pharmacokinetic data
Elimination half-life90 minutes
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar massapprox. 131 kg/mol
  (verify)

Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations.

Anistreplase is used to treat blood clots in emergency situations such as myocardial infarction.[1] Early treatment gives better outcomes.[1]

History

[edit | edit source]

Anistreplase has been developed by Beecham under the brand name Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) after its components.[1][2][3]

References

[edit | edit source]
  1. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).